Type of Content
Approved Story
1
Format
Region
News Item Format
Standard
With vaccine immunity waning, and concerns over a fall surge growing, officials from Moderna announced on Wednesday that data from its study on Omicron-containing bivalent booster, revealed that it offers superior antibody response against omicron – one month after injection - compared to the company's current vaccine.
Moderna Chief Medical Officer Dr. Paul Burton told ABC News that he believes the company's "highly effective" updated COVID-19 bivalent vaccine could be a "turning point" in the nation's fight against the pandemic.
"The data are definitely better than I had even hoped," Burton told ABC News that in an interview. "Given the magnitude of effect — that seven-fold increase in antibody levels — we could for the first time, be at a vaccine that is truly effective with once yearly dosing because we know those antibody levels will decay."